Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Inventory (2024 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Change in Inventory for 2 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory rose 68.64% to $9.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.0 million through Dec 2025, up 269.82% year-over-year, with the annual reading at $22.0 million for FY2025, 269.82% up from the prior year.
  • Change in Inventory hit $9.7 million in Q4 2025 for ARS Pharmaceuticals, up from -$963000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $9.7 million in Q4 2025 to a low of -$963000.0 in Q3 2025.